BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Guardian Technology Partners, LLC Announces Completed Intellectual Property License Agreement


10/19/2005 5:09:17 PM

BERWYN, Pa.--(BUSINESS WIRE)--Nov. 25, 2003--Guardian Technology Partners, LLC, a leading Intellectual Property (IP) licensing firm, reported today it has successfully completed a technology license agreement in the area of pharmaceutical research and development. The agreement, between Guardian's client, a global chemical company with annual sales in excess of $15 billion, and a multi-billion dollar global pharmaceutical company, was facilitated, negotiated and executed through the work of Guardian Technology Partners. The IP licensing process was managed by Peter Haabestad, Founder and Managing Director of Guardian Technology Partners. "We are pleased to be able to support our clients in their efforts to out-license valuable Intellectual Property portfolios and create additional revenue streams in non-core markets," said Haabestad. Although the terms of the deal were not disclosed, Guardian's global chemical client has extended Guardian's engagement and has stated it plans to add additional IP portfolios to Guardian's scope.

Intellectual Property is rapidly becoming the core source of wealth creation in many sectors of the world-wide economy. Today, valuation of corporate entities is primarily based upon the intangible assets of the firm, versus tangible asset valuation techniques of years past. This trend underscores the importance of IP management including know-how, patents, copyrights and trade secrets. Today's leading-edge technology companies must respond quickly and wisely to the IP call to arms and employ programs to maximize the protection and subsequent leverage of these intangible assets.

About the Company

Guardian Technology Partners is a leading licensing and commercialization firm of underleveraged Intellectual Property (IP) primarily into the pharmaceutical/biotechnology and life sciences marketplace. Guardian is comprised of a team of professionals drawn from medicine, science, technology, strategy, sales and marketing, and finance. Guardian follows the highest ethical and professional standards in representing its client's interests and their IP assets. Guardian provides broad technical expertise, strong business development skills, industry wide contacts, licensing know-how and a commitment to success. www.gtpllc.com

Contact:

Guardian Technology Partners, LLC, Berwyn Peter H. Haabestad, 610-647-6000 info@gtpllc.com

Source: Guardian Technology Partners, LLC



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES